person · Reporting owner

Ingram Elizabeth Garrett

Disclosed activity across 2 companies

Tapewire entity: 154981
SEC CIK: 0001743688

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
AVENUE THERAPEUTICS, INC.ATXI · Entity 8537	Director	September 12, 2019	September 16, 2019
MANNKIND CORPMNKD · Entity 4792	Chief Marketing Officer	May 14, 2019	May 16, 2019

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

AVENUE THERAPEUTICS, INC.

Report date September 12, 2019 · Filed September 16, 2019

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	16,000	Reported balance After 2019-09-12 transaction · row 1 1 source row Row 1 · 2019-09-12 · Purchase · Acquired 16,000 · Balance 16,000

MANNKIND CORP

Report date May 14, 2019 · Filed May 16, 2019

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.32 · Expires 2029-05-14	Direct	105,000	Reported balance After 2019-05-14 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2019-05-14 · Grant · Acquired 105,000 · Balance 105,000 F1: Annual Equity Award: 25% vesting on the anniversary of the vesting determination date and 1/48th per month thereafter; being fully vested on the fourth anniversary of the vesting determination date.

Filing footnotes · ownership attribution and instrument terms

F1: Annual Equity Award: 25% vesting on the anniversary of the vesting determination date and 1/48th per month thereafter; being fully vested on the fourth anniversary of the vesting determination date.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
September 12, 2019 Filed Sep 16, 2019 16:16 UTC	AVENUE THERAPEUTICS, INC. ATXI · Entity 8537	PurchaseCommon Stock	16,000	$6.27	$100,320.00	Disclosure SEC source: 0001144204-19-044714 · tv529486_form4.xml · nonDerivative · entry 1 Ingram Elizabeth Garrett · CIK 0001743688 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Read SEC document
May 14, 2019 Filed May 16, 2019 20:24 UTC	MANNKIND CORP MNKD · Entity 4792	GrantEmployee Stock Option (right to buy) · Derivative	105,000	$1.32 Strike: $1.32	$138,600.00	Disclosure SEC source: 0001209191-19-030377 · doc4.xml · derivative · entry 1 Ingram Elizabeth Garrett · CIK 0001743688 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,000 Underlying: Stock Options · 105,000 shares Expires 2029-05-14 F1 · kind: Annual Equity Award: 25% vesting on the anniversary of the vesting determination date and 1/48th per month thereafter; being fully vested on the fourth anniversary of the vesting determination date. Read SEC document
February 20, 2019 Filed Feb 25, 2019 11:04 UTC	MANNKIND CORP MNKD · Entity 4792	GrantRestricted Stock Unit	11,871	$0.00	$0.00	Disclosure SEC source: 0001209191-19-012813 · doc4.xml · nonDerivative · entry 1 Ingram Elizabeth Garrett · CIK 0001743688 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,012 F1 · shares: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F2 · shares: Restricted stock units shall vest and be delivered on February 20, 2020. Read SEC document
January 31, 2019 Filed Jan 31, 2019 23:11 UTC	MANNKIND CORP MNKD · Entity 4792	PurchaseCommon Stock, $.01 Par Value	5,000	$1.07	$5,350.00	Disclosure SEC source: 0001209191-19-006270 · doc4.xml · nonDerivative · entry 1 Ingram Elizabeth Garrett · CIK 0001743688 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,141 F1 · kind: The reporting person purchased shares through the Company's Employee Stock Purchase Plan on January 31, 2019 representing the maximum allowable under the Plan for this period. Read SEC document
August 22, 2018 Filed Aug 24, 2018 00:10 UTC	MANNKIND CORP MNKD · Entity 4792	GrantEmployee Stock Option (right to buy) · Derivative	117,000	$1.10 Strike: $1.10	$128,700.00	Disclosure SEC source: 0001209191-18-048280 · doc4.xml · derivative · entry 1 Ingram Elizabeth Garrett · CIK 0001743688 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,000 Underlying: Stock Options · 117,000 shares Expires 2028-06-01 F1 · kind: 25% vesting on the anniversary of the vesting determination date and 1/48th per month thereafter; being fully vested on the fourth anniversary of the vesting determination date. Read SEC document
June 14, 2018 Filed Jun 14, 2018 20:57 UTC	MANNKIND CORP MNKD · Entity 4792	GrantCommon Stock, $0.01 Par Value	26,041	$1.92	$49,998.72	Disclosure SEC source: 0001209191-18-037771 · doc4.xml · nonDerivative · entry 1 Ingram Elizabeth Garrett · CIK 0001743688 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,141 Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.